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1524Objective: This study was performed to assess the Society of Thoracic Surgeons (STS) score as a measure of
successful adoption of transapical transcatheter aortic valve implantation (TAVI).
Methods: The STS score for estimated surgical mortality was calculated and used to select the first 140 consec-
utive patients undergoing transapical TAVI. The STS score also was used to estimate postoperative morbidity.
The comparisons were made between the observed and estimated mortality and morbidity in the entire group, as
well as in the first 35, second 35, and last 70 consecutive patients.
Results: The differences in outcomes between the first 35, second 35, and last 70 patients were statistically sig-
nificant for surgical mortality (20.0% vs 14.3% vs 2.9%; P¼ .045), composite morbidity/mortality (34.3% vs
40.1% vs 15.7%; P¼ .020), and long length of stay (34.3% vs 45.7% vs 18.6%; P¼ .027). There were trends
of marked decreases in prolonged ventilation (11.4% vs 20.0% vs 4.3%; P ¼ .061), and acute renal failure
(14.3% vs 20.0% vs 4.3%; P ¼ .059). In the first 70 patients there were no significant differences between ob-
served and STS estimated incidences in mortality and composite mortality/major morbidity. In the latter 70 pa-
tients the observed incidences were lower than STS predicted values in mortality (2.9% vs 9.6%; P ¼ .056),
composite major morbidity/mortality (15.7% vs 33.8%; P ¼ .001), and prolonged ventilation (4.3% vs
25.1%; P<.0001).
Conclusions: Only after a protracted learning curve did the anticipated benefits of transapical TAVI
materialize for patients at high risk for surgery as predicted by the STS risk algorithms. (J Thorac Cardiovasc
Surg 2014;147:1524-8)Transapical transcatheter aortic valve implantation (TAVI)
is a new modality for the treatment of symptomatic aortic
valve stenosis.1 Clinical experience therefore remains lim-
ited and predicting the risk of morbidity and/or mortality af-
ter transapical TAVI, particularly in any one patient, is
difficult. Early studies2 showed the efficacy of the proce-
dure, but a more recent randomized trial3 showed only its
equivalence to surgical aortic valve replacement (AVR) in
high-risk surgical patients. To date, however, the number
of patients studied has been comparatively small and there-
fore formulation of a unique transapical TAVI risk algo-
rithm for predicting outcomes for this procedure will have
to await enrolment of a considerably larger number of
patients.
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The Journal of Thoracic and Cardiovascular Surthe Society of Thoracic Surgeons (STS) score, has been
used to help identify nonsurgical patients and those
at high risk for surgical AVR before counseling for a trans-
catheter approach.2-4 This study aimed to evaluate the
earlier-described widely used and validated STS score
risk-stratification model formulated for cardiac surgery as
a measure of the anticipated benefits of transapical TAVI
versus that predicted for surgical AVR.
PATIENTS AND METHODS
Between October 2005 and March 2011, a total of 140 consecutive pa-
tients underwent transapical TAVI. The patient characteristics (Table 1)
were used to determine the STS score for expected surgical mortality, com-
posite morbidity and 30-day mortality, neurologic injury, acute renal fail-
ure, prolonged ventilation, reoperation, length of stay, and sternal wound
infection for surgical AVR.5 To evaluate the predictive value of the surgical
risk algorithm for transapical TAVI, comparisons were made between the
observed and estimated mortality and morbidity in transapical TAVI
patients. In addition, to evaluate the impact of the learning curve on the
expected better outcomes with TAVI in this high-risk surgical cohort, the
study cohort was divided into 3 subgroups: first 35, second 35, and last
70 consecutive patients. The observed mortality and morbidity were
compared between the 3 groups and within each group with the predicted
mortality and morbidity from the STS scores.
All data were collected prospectively and were summarized using fre-
quency and percentage for categoric variables and mean  standard devi-
ation for continuous variables. The c2 test was used to compare the
observed number of events from TAVI with the expected number of events
calculated from the STS scores for surgical AVR. Logistic regression anal-
ysis was performed for comparisons of the observed outcomes between thegery c May 2014
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dicted outcomes from STS scores. A P value less than .05 indicated a sta-
tistically significant difference. All analyses were performed using SAS
version 9.3 (Cary, NC).A
C
DRESULTS
The mean patient age was 79.7  8.2 years and 82 of the
140 patients were women (Table 1). In the overall 140
patients, there was no significant difference between the
observed mortality after transapical TAVI (10.7%) and
the estimated mortality for surgical AVR by the STS score
(10.0; P ¼ .866) (Table 2). In addition, the STS risk algo-
rithm was used to calculate composite surgical morbidity
and mortality, and major complications including neuro-
logic injury, renal failure, prolonged ventilation, need for
reoperation, and length of stay.5 There were no statistical
differences in permanent stroke, renal failure, length of
stay, and wound infection between the estimated incidence
for surgical AVR and observed values in transapical TAVI.
In contrast, the STS estimated composite surgical mortality
and morbidity, prolonged ventilation, and reoperation were
significantly higher for surgical AVR than the observed
values for transapical TAVI (Table 2).
The differences in outcomes between the first 35, second
35, and last 70 patients, controlling for corresponding pre-
dicted risk scores, were statistically significant for surgical
mortality (20.0% vs 14.3% vs 2.9%; P¼ .045), composite
morbidity/mortality (34.3% vs 40.1% vs 15.7%;
P ¼ .020), and long length of stay (34.3% vs 45.7% vs
18.6%; P ¼ .027). There were trends for marked decreases
in prolonged ventilation (11.4% vs 20.0% vs 4.3%;
P ¼ .061), and acute renal failure (14.3% vs 20.0% vs
4.3%; P ¼ .059). There were no statistically significant
differences between the first and second halves of the study
cohort for permanent stroke or re-operation (Table 3).
For outcomes with a significant difference between the 3
study cohorts, the comparison between the observed and
predicted event rate also was performed separately for
each cohort. The observed surgical mortality after transap-
ical TAVI and the STS estimated surgical mortality for sur-
gical AVRwere 20.0% versus 11.4% (P¼ .107) for the first
35 patients, 14.3% versus 9.6% for the second 35 patients
(P¼ .346), and 2.9% versus 9.6% (P¼ .056) for the last 70
patients. The difference between the observed incidence of
composite mortality and major morbidity and the STS esti-
mated incidences for surgical AVR was statistically signif-
icant only in the last 70 patients. The observed and STSThe Journal of Thoracic and Carpredicted incidence of prolonged ventilation was signifi-
cantly different in both the first 35 patients and the last 70
patients. There was a trend toward a marked decrease in
the observed acute renal failure compared with the STS pre-
dicted incidence only in the last 70 patients (Table 4).
DISCUSSION
In cardiac surgery, the most commonly used risk algo-
rithm is the STS score.5 This algorithm has proven to be im-
portant when it comes to predicting surgical mortality and
postoperative complications in cardiac surgery. The algo-
rithm is generated using large patient databases5 that incor-
porate characteristics related to the patient as well as the
procedure, and the characteristics found to be predictive
of outcomes are added to the total risk calculation when
assessing any given patient’s risk for a cardiac surgery pro-
cedure. Large patient databases are required because with-
out a large sample, the prediction of uncommon outcomes
including mortality is difficult.
Mortality
We used the STS risk algorithm to initially identify high-
risk surgical patients for transapical TAVI and then evalu-
ated the predictive accuracy of the same surgical risk
algorithm for outcomes in an essentially nonsurgical proce-
dure (transapical TAVI). We fully expected an immediate
and obvious benefit reflected in a decreased mortality rate
with transapical TAVI. Considering our entire cohort of
140 patients who underwent transapical TAVI, the STS
score estimated mortality for surgical AVRwas very similar
to the observed mortality with apparent little benefit attrib-
utable to the transapical TAVI methodology. Indeed, the ob-
served surgical mortality was higher than the STS predicted
mortality in the first 35 and second 35 cases, with only
a trend to a decrease in observed surgical mortality from
the first 35 patients to the second 35 patients. There was,
however, a significant decrease in observed surgical mortal-
ity from the first 70 patients to the last 70 patients despite
similar patient characteristics and a similar estimated mor-
tality by the STS score for surgical AVR. Therefore, the
benefits of the transapical TAVI approach in this high-risk
surgical group became evident only after the first 70 pa-
tients. This suggests a significant continuing learning curve
from initially adopting to finally mastering transapical
TAVI. The STS score estimated mortality for surgical
AVR was 3 times higher than the observed mortality for
the transapical TAVI approach in the last 70 patients
(Table 4).
This study suggests that in a high-risk elderly and fragile
cohort of patients with numerous comorbidities, patient risk
factors initially may far outweigh any anticipated early pro-
cedural benefits, particularly if there is unfamiliarity with
the procedure. This may well explain the lack of difference
in mortality we observed in the first 70 patients between thediovascular Surgery c Volume 147, Number 5 1525
TABLE 3. The first 35, second 35, and last 70 patients
30-Day mortality and
morbidity
Patients
P value*1-35 36-70 71-140
Mortality 20.0 14.3 2.9 .045
Permanent stroke 2.9 2.9 2.9 .998
Renal failure 14.3 20.0 4.3 .059
Prolonged ventilation 11.4 20.0 4.3 .061
Reoperation 2.9 5.7 5.7 .867
Major morbidity or mortality 34.3 40.1 15.7 .020
Long length of stay (>14 d) 34.3 45.7 18.6 .027
Short length of stay (<5 d) 31.4 11.4 15.7 .063
DSW infection 0 0 0
DSW, Deep sternal wound. *P value was obtained by logistic regression analysis,
adjusting for corresponding Society of Thoracic Surgeons predicted risk.
TABLE 1. Patient and procedural risk factors
Calculation of STS Mean ± SD or number (%)
Risk factors included
Age (y) 79.7  8.2
Female 86 (61.4)
Weight/body surface area 68.3  19.1/1.7  0.3
Intra-aortic balloon pump/inotropes
or emergency surgery
0 (0)
Left ventricular ejection fraction 53.9  13.2
Renal function averaged creatinine
level
120.2  71.6
Creatinine level>100 72 (51.4)
Lung disease 55 (39.3)
Peripheral vascular disease 86 (61.4)
Diabetes 46 (32.9)
Neurologic dysfunction 37 (26.4)
Active endocarditis 0 (0)
Unstable angina or recent myocardial
infarction
39 (27.9)
Previous cardiac surgery 74 (52.9)
Valve surgery 141 (100)
Atrial fibrillation 56 (40)
Risk factors not included
Porcelain aorta 34 (24.3)
Hypertension 124 (88.6)
Pulmonary hypertension (not in STS):
average
45.3  15.8
60 mm Hg 25 (17.9)
Recent history of gastrointestinal
bleeding
19 (13.6)
STS, Society of Thoracic Surgeons; SD, standard deviation.
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tial benefit attributable to the former. The term minimally
invasive applies to a given procedure’s method of accessing
the tissue of interest and may not accurately represent the
insult to the patient while the procedure is being learned
and perfected. The high-risk patients in this study, many
deemed nonsurgical by 2 senior surgeons, went on to have
a minithoracotomy, the apex of the left ventricle wasTABLE 2. Predicted versus observed postoperative mortality and
morbidities in all 140 patients
30-Day mortality and
morbidity Predicted (%) Observed (%) P value
STS score 10.0 10.7 .866
Permanent stroke 3.6 2.9 .853
Renal failure* 10.7 10.7 1.0
Prolonged ventilation 25.9 10.0 <.001
Reoperation 13.3 5.0 .002
Major morbidity or mortality 34.8 26.4 .042
Long length of stay (>14 d) 18.3 21.4 .394
Short length of stay (<5 d) 16.2 18.6 .516
DSW infection 0.3 0 1.0
STS, Society of Thoracic Surgeons; DSW, deep sternal wound. *Renal failure was
defined as meeting 1 or more of the following criteria: (1) increase in serum creatinine
level to 2.0 or more times the preoperative creatinine level; or (2) new requirement for
dialysis.
1526 The Journal of Thoracic and Cardiovascular Surmanipulated, a large catheter was placed in the left ventri-
cle, the stenotic aortic valve was crossed and further ob-
structed, and rapid ventricular pacing to reduce cardiac
output induced significant hypotension during deployment
of the transcatheter valve. Although perceived as minimally
invasive, the early experience with a less-controlled trans-
apical TAVI approach may in fact be physiologically
more invasive in this patient group than a well-controlled
circulatory supported open surgical procedure.
Risk models implicitly assume expertise of the surgeons
and experience and familiarity of the team with the proce-
dure. This study suggests that the anticipated less-
complex and less-invasive procedure was perhaps initially
affected negatively by the necessary learning curve that ac-
companies any new approach. This was indicated by the
higher mortality rate found in the first 15 patients (33%)
treated compared with the almost one third of the mortality
rate in those patients who followed afterward,6 and, simi-
larly, the mortality in the first 35 patients (20%) compared
with the one seventh of the mortality rate in the last 70 pa-
tients, even though the patients had nearly identical risk pro-
files. The significantly improved outcomes of transapical
TAVI in the later cases likely is owing to the cumulative ex-
perience of the TAVI team. Because we were among the
very early adopters of transapical TAVI in human beings,
our initial learning curve may have been longer than subse-
quent newer TAVI centers coming on board that have
benefited from our experience and also availed themselves
of the now available enhanced training and proctoring. Im-
portant factors that may reduce the learning curve dramati-
cally include the following: (1) collaborative team work, (2)
training and proctoring, (3) carefully screening patients for
risks and contraindications, (4) meticulous attention to
details during TAVI procedures, (5) a clearly discussed
back-up plan for each patient, and (6) carefully monitored
postoperative care.
Morbidity
We used the STS predictive risk model developed for cor-
onary bypass surgery to assess the predicted incidence ofgery c May 2014
TABLE 4. Predicted versus observed mortality and morbidities in the first 35, second 35, and last 70 patients
30-Day mortality and
morbidity
Patients
1-35 36-70 71-140
Predicted
(%)
Observed
(%) P value
Predicted
(%)
Observed
(%) P value
Predicted
(%)
Observed
(%) P value
Mortality 11.4 20.0 .107 9.6 14.3 .346 9.6 2.9 .056
Renal failure 11.9 14.3 .661 9.4 20.0 .033 10.8 4.3 .081
Prolonged ventilation 28.2 11.4 .027 24.9 20.0 .502 25.1 4.3 <.0001
Major morbidity or mortality 38.2 34.3 .635 33.5 40.0 .418 33.8 15.7 .001
Permanent stroke 4.3 2.9 .680 3.8 2.9 .771 3.2 2.9 .872
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lation of composite morbidity and 30-day postoperative
mortality, as well as postoperative neurologic injury, renal
failure, prolonged ventilation, reoperation, the length of
hospital stay, and sternal wound infection. Interestingly,
the STS risk algorithm seems to predict the incidence of
postoperative stroke in transapical TAVI regardless of the
purported learning curve. The incidence of stroke at 30
days postprocedure in this study was similar to that pre-
dicted by the algorithm for surgical AVR for all patient co-
horts and similar to the results recently reported in
a randomized controlled trial with transcatheter valves.3
The length of hospital stay is subjective and also dependent
onmany additional factors such as the availability of a social
support program, presence of an intermediate-care facility,
and the medical insurance systems. Despite these factors,
the rate of long length of stay still decreased significantly
after the first 70 cases compared with the predicted value
by the STS surgical risk algorithm. Similar to the trend of
surgical mortality in this study, the significant decrease in
composite mortality and major morbidity was observed
only after the first 70 cases. Other surgical morbidities,
such as prolonged ventilation and acute renal failure, also
were markedly lower than the predicted values by the
STS risk algorithm because the procedure was learned
and better exercised. This study has shown that not only sur-
gical mortality but also major morbidities have to be consid-
ered when assessing the successful adoption and mastering
of any new surgical procedure, such as transapical TAVI.
Compared with previous studies,7 the uniqueness of this
study was in the comparison of the predicted values by
the surgical STS score with the observed values for both
mortality and morbidity as an indicator of successful adop-
tion and mastery of the procedure.
In this study, our threshold to master the transapical
procedure was a learning curve of approximately 70
cases. Generally speaking, 70 cases is not a large number
to master a new complex surgical procedure, such as
transapical TAVI. Other approaches, such as direct aortic
and subclavian artery approaches, may have relatively
shorter learning curves. However, after mastering the
transapical approach, we believe that the direct aortic orThe Journal of Thoracic and Carsubclavian artery approach is not necessarily an easier
alternate access option compared with the transapical
approach.
Limitations
Patient frailty, a frequently used descriptor, was as-
sessed subjectively by experienced cardiac surgeons, but
not standardized with a frailty index in these patients.
Frailty, readily recognized but hard to define or quantitate,
also is not included in the STS risk algorithm. Therefore,
this patient characteristic may not have been the same in
all 3 study groups despite similar STS scores. Further-
more, other risks such as severe chronic obstructive pul-
monary disease, severe peripheral vascular disease,
calcified ascending aorta, dementia, and prolonged preop-
erative hospitalization were not included or weighted ap-
propriately in the STS surgical risk algorithm, which
might have resulted in differences in patient characteristics
among the 3 study groups. Our subjective patient selection
criteria might indeed have evolved over time, however, the
predicted mortality by the objective STS score remained
similar among subgroups. Finally, because of our early in-
troduction to clinical transapical TAVI, the prolonged
learning curve suggested by this study may no longer be
applicable to many new centers that can benefit from the
now available detailed proctoring and intense training.
Proctoring and training likely shortens the initial learning
curve, but may not significantly shorten the course of mas-
tering the procedure.
SUMMARY
The risk stratification model used to predict outcomes in
cardiac surgery is based on patients undergoing sternotomy,
cardiopulmonary bypass, cross-clamping of the aorta, car-
dioplegia of the heart, opening of the aorta, excising of
the sclerosed valve, implanting a new aortic prosthesis, clo-
sure of the aorta, and discontinuance from cardiopulmonary
bypass. It is reasonable to assume then that the risk algo-
rithms would overestimate the observedmorbidity andmor-
tality in the presumed less-invasive transapical TAVI
procedure. However, the expected overestimation did not
materialize when we compared the predictions made ondiovascular Surgery c Volume 147, Number 5 1527
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served experience with transapical TAVI in the first 70 pa-
tients. Once the nuances of the procedure were mastered
and experience was gained with trouble spots, as in our
last 70 patients, we seemed more able to better capitalize
on the benefits to be reaped from the less-invasive transap-
ical TAVI.
The number of patients treated with TAVI, both trans-
apical and transfemoral,8 remains comparatively small
and there are limited data from which to generate unique
risk algorithms for this procedure. Our study indicates
that the most commonly used STS surgical risk algorithm
fails to predict outcomes for transapical TAVI, particu-
larly after the transapical procedure has been mastered.
Therefore, the STS cardiac surgery risk algorithm may
be used as a gauge to indicate institutional program posi-
tion along the learning curve of transapical TAVI. Agree-
ment between observed and predicted surgical risk of
mortality, renal failure, prolonged ventilation, and com-
posite major morbidity and mortality suggests a need
for further learning. Consistent significant overestimation
of the earlier-described morbidities and mortality by the
STS surgical risk algorithm suggests successful adoption1528 The Journal of Thoracic and Cardiovascular Surand mastering of transapical TAVI or similarly any new
less-invasive technology.References
1. Ye J, Cheung A, Lichtenstein SV, Carere RG, Thompson CR, Pasupati S, et al.
Transapical aortic valve implantation in humans. J Thorac Cardiovasc Surg.
2006;131:1194-6.
2. Svensson LG, Dewey T, Kapadia S, Roselli EE, Stewart A, Williams M, et al.
United States feasibility study of transcatheter insertion of a stented aortic valve
by the left ventricular apex. Ann Thorac Surg. 2008;86:46-54.
3. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al;
PARTNER Trial Investigators. Transcatheter versus surgical aortic-valve replace-
ment in high-risk patients. N Engl J Med. 2011;364:2187-98.
4. Dewey TM, Brown D, RyanWH, Herbert MA, Prince SL, MackMJ. Reliability of
risk algorithms in predicting early and late operative outcomes in high-risk patients
undergoing artic valve replacement. J Thorac Cardiovasc Surg. 2008;135:180-7.
5. Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, Chen A, et al;
Society of Thoracic Surgeons. The Society of Thoracic Surgeons: 30-day opera-
tive mortality and morbidity risk models. Ann Thorac Surg. 2003;75:1856-64.
6. Ye J, Cheung A, Lichtenstein SV, Nietlispach F, Albugami S, Masson JB, et al.
Transapical transcatheter aortic valve implantation: follow-up to 3 years. J Thorac
Cardiovasc Surg. 2010;139:1107-13.
7. Gurvitch R, Tay EL,Wijesinghe N, Ye J, Nietlispach F,Wood DA, et al. Transcath-
eter aortic valve implantation: lessons from the learning curve of the first 270
high-risk patients. Catheter Cardiovasc Interv. 2011;78:977-84.
8. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al;
PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic
stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:
1597-607.gery c May 2014
